Intravitreal and Intracameral DEX in NPDR

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

April 20, 2025

Study Completion Date

June 1, 2025

Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
DRUG

Dexamethasone sodium phosphate

In patients with stable DR and no significant macular edema, intravitreal anti-VEGF injections after phacoemulsification surgery can prevent the worsening of postoperative macular edema and potentially improve final visual outcomes while maintaining safety. Laser coagulation and intravitreal anti-VEGF injections are currently considered the standard treatments for PDR. However, the cost of anti-VEGF drugs often prevents many patients from receiving regular and timely injections. Intravitreal corticosteroids may be used as an alternative to anti-VEGF agents.

Trial Locations (1)

226001

Eye Institute, Affiliated Hospital of Nantong University, Nantong

All Listed Sponsors
lead

Affiliated Hospital of Nantong University

OTHER